{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:11:06Z","timestamp":1770966666057,"version":"3.50.1"},"reference-count":32,"publisher":"American Diabetes Association","issue":"7","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:p>Diabetic nephropathy is currently the most common cause of end-stage renal disease (ESRD) in the western world. A mouse model for diabetic nephropathy that encompasses the salient features of this disease in the kidney is not available. Here, we report that CD1 mice, in contrast to inbred C57BL\/6 and 129Sv strains, develop ESRD associated with prominent tubulointerstitial nephritis and fibrosis within 3 months and die because of diabetic complications by 6\u20137 months after a single injection of streptozotocin. Histopathologic lesions observed in these mice mimic human diabetic nephropathy, including glomerular hypertrophy, diffuse glomerulosclerosis, tubular atrophy, interstitial fibrosis, and decreased renal excretory function. Next, we tested the therapeutic efficacy of bone morphogenic protein-7 (BMP-7) and inhibitors of advanced glycation end products (AGEs), aminoguanidine and pyridoxamine, to inhibit and regress the progression of renal disease in diabetic CD1 mice. We demonstrate that although aminoguanidine, pyridoxamine, and BMP-7 significantly inhibit glomerular lesions, BMP-7 is most effective in the inhibition of tubular inflammation and tubulointerstitial fibrosis in these mice. Collectively, our results report a new mouse model for diabetic nephropathy with prominent interstitial inflammation and fibrosis and the selective inhibition of diabetic kidney disease by AGE inhibitors and BMP-7.<\/jats:p>","DOI":"10.2337\/db06-1226","type":"journal-article","created":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T16:33:45Z","timestamp":1182962025000},"page":"1825-1833","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":175,"title":["Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors"],"prefix":"10.2337","volume":"56","author":[{"given":"Hikaru","family":"Sugimoto","sequence":"first","affiliation":[{"name":"Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}]},{"given":"Gordan","family":"Grahovac","sequence":"additional","affiliation":[{"name":"Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}]},{"given":"Michael","family":"Zeisberg","sequence":"additional","affiliation":[{"name":"Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}]},{"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[{"name":"Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts"},{"name":"Harvard\u2013Massachusetts Institute of Technology Division of Health Sciences and Technology, Boston, Massachusetts"}]}],"member":"1167","reference":[{"key":"2022031208181464500_R1","doi-asserted-by":"crossref","unstructured":"Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis\u200834:795\u2013808,1999","DOI":"10.1016\/S0272-6386(99)70035-1"},{"key":"2022031208181464500_R2","doi-asserted-by":"crossref","unstructured":"Fioretto P, Kim Y, Mauer M: Diabetic nephropathy as a model of reversibility of established renal lesions. Curr Opin Nephrol Hypertens\u20087:489\u2013494,1998","DOI":"10.1097\/00041552-199809000-00001"},{"key":"2022031208181464500_R3","doi-asserted-by":"crossref","unstructured":"Fioretto P, Sutherland DE, Najafian B, Mauer M: Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int\u200869:907\u2013912,2006","DOI":"10.1038\/sj.ki.5000153"},{"key":"2022031208181464500_R4","doi-asserted-by":"crossref","unstructured":"Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K: Mouse models of diabetic nephropathy. J Am Soc Nephrol\u200816:27\u201345,2005","DOI":"10.1681\/ASN.2004080648"},{"key":"2022031208181464500_R5","doi-asserted-by":"crossref","unstructured":"Young BA, Maynard C, Boyko EJ: Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care\u200826:2392\u20132399,2003","DOI":"10.2337\/diacare.26.8.2392"},{"key":"2022031208181464500_R6","doi-asserted-by":"crossref","unstructured":"Mauer SM, Lane P, Zhu D, Fioretto P, Steffes MW: Renal structure and function in insulin-dependent diabetes mellitus in man. J Hypertens Suppl\u200810:S17\u2013S20,1992","DOI":"10.1097\/00004872-199204001-00004"},{"key":"2022031208181464500_R7","doi-asserted-by":"crossref","unstructured":"Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia\u200842:878\u2013886,1999","DOI":"10.1007\/s001250051241"},{"key":"2022031208181464500_R8","doi-asserted-by":"crossref","unstructured":"Metz TO, Alderson NL, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys\u2008419:41\u201349,2003","DOI":"10.1016\/j.abb.2003.08.021"},{"key":"2022031208181464500_R9","doi-asserted-by":"crossref","unstructured":"Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller GA, Kalluri R: Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol\u2008285:F1060\u2013F1067,2003","DOI":"10.1152\/ajprenal.00191.2002"},{"key":"2022031208181464500_R10","doi-asserted-by":"crossref","unstructured":"Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem\u2008278:12605\u201312608,2003","DOI":"10.1074\/jbc.C300012200"},{"key":"2022031208181464500_R11","doi-asserted-by":"crossref","unstructured":"Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R: Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A\u2008103:7321\u20137326,2006","DOI":"10.1073\/pnas.0601436103"},{"key":"2022031208181464500_R12","doi-asserted-by":"crossref","unstructured":"Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med\u20089:964\u2013968,2003","DOI":"10.1038\/nm888"},{"key":"2022031208181464500_R13","unstructured":"Brocco E, Fioretto P, Mauer M, Saller A, Carraro A, Frigato F, Chiesura-Corona M, Bianchi L, Baggio B, Maioli M, Abaterusso C, Velussi M, Sambataro M, Virgili F, Ossi E, Nosadini R: Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int Suppl\u200863:S40\u2013S44,1997"},{"key":"2022031208181464500_R14","doi-asserted-by":"crossref","unstructured":"Kushiro M, Shikata K, Sugimoto H, Ikeda K, Horiuchi S, Makino H: Accumulation of Nsigma-(carboxy-methyl)lysine and changes in glomerular extracellular matrix components in Otsuka Long-Evans Tokushima fatty rat: a model of spontaneous NIDDM. Nephron\u200879:458\u2013468,1998","DOI":"10.1159\/000045093"},{"key":"2022031208181464500_R15","doi-asserted-by":"crossref","unstructured":"Leiter EH: Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc Natl Acad Sci U S A\u200879:630\u2013634,1982","DOI":"10.1073\/pnas.79.2.630"},{"key":"2022031208181464500_R16","doi-asserted-by":"crossref","unstructured":"Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest\u200874:1143\u20131155,1984","DOI":"10.1172\/JCI111523"},{"key":"2022031208181464500_R17","doi-asserted-by":"crossref","unstructured":"Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM: Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med\u2008320:966\u2013970,1989","DOI":"10.1056\/NEJM198904133201503"},{"key":"2022031208181464500_R18","unstructured":"Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P: Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab\u200826 (Suppl. 4):8\u201314,2000"},{"key":"2022031208181464500_R19","doi-asserted-by":"crossref","unstructured":"Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes\u200845:522\u2013530,1996","DOI":"10.2337\/diabetes.45.4.522"},{"key":"2022031208181464500_R20","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes\u200853:1831\u20131840,2004","DOI":"10.2337\/diabetes.53.7.1831"},{"key":"2022031208181464500_R21","doi-asserted-by":"crossref","unstructured":"Kume E, Doi C, Itagaki S, Nagashima Y, Doi K: Glomerular lesions in unilateral nephrectomized and diabetic (UN-D) mice. J Vet Med Sci\u200854:1085\u20131090,1992","DOI":"10.1292\/jvms.54.1085"},{"key":"2022031208181464500_R22","doi-asserted-by":"crossref","unstructured":"McGowan TA, Zhu Y, Sharma K: Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep\u20084:447\u2013454,2004","DOI":"10.1007\/s11892-004-0055-z"},{"key":"2022031208181464500_R23","doi-asserted-by":"crossref","unstructured":"Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db\/db diabetic mice. Proc Natl Acad Sci U S A\u200897:8015\u20138020,2000","DOI":"10.1073\/pnas.120055097"},{"key":"2022031208181464500_R24","doi-asserted-by":"crossref","unstructured":"Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes\u200851:2826\u20132832,2002","DOI":"10.2337\/diabetes.51.9.2826"},{"key":"2022031208181464500_R25","doi-asserted-by":"crossref","unstructured":"Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW: Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem\u2008278:42012\u201342019,2003","DOI":"10.1074\/jbc.M304292200"},{"key":"2022031208181464500_R26","doi-asserted-by":"crossref","unstructured":"Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol\u2008279:F130\u2013F143,2000","DOI":"10.1152\/ajprenal.2000.279.1.F130"},{"key":"2022031208181464500_R27","doi-asserted-by":"crossref","unstructured":"Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, Phan SH, Park JM, Dressler GR: Kielin\/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med\u200811:387\u2013393,2005","DOI":"10.1038\/nm1217"},{"key":"2022031208181464500_R28","doi-asserted-by":"crossref","unstructured":"Wang S, Hirschberg R: Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem\u2008279:23200\u201323206,2004","DOI":"10.1074\/jbc.M311998200"},{"key":"2022031208181464500_R29","doi-asserted-by":"crossref","unstructured":"Zeisberg M: Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant\u200821:568\u2013573,2006","DOI":"10.1093\/ndt\/gfk010"},{"key":"2022031208181464500_R30","doi-asserted-by":"crossref","unstructured":"Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, Hruska KA: Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int\u200863:2037\u20132049,2003","DOI":"10.1046\/j.1523-1755.2003.00035.x"},{"key":"2022031208181464500_R31","doi-asserted-by":"crossref","unstructured":"Stoppa GR, Cesquini M, Roman EA, Ogo SH, Torsoni MA: Aminoguanidine prevented impairment of blood antioxidant system in insulin-dependent diabetic rats. Life Sci\u200878:1352\u20131361,2006","DOI":"10.1016\/j.lfs.2005.07.031"},{"key":"2022031208181464500_R32","doi-asserted-by":"crossref","unstructured":"Voziyan PA, Hudson BG: Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci\u20081043:807\u2013816,2005","DOI":"10.1196\/annals.1333.093"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/56\/7\/1825\/388443\/zdb00707001825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/56\/7\/1825\/388443\/zdb00707001825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:09:29Z","timestamp":1667405369000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/56\/7\/1825\/12585\/Renal-Fibrosis-and-Glomerulosclerosis-in-a-New"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db06-1226","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}